[A17-40] Daratumumab (multiple myeloma) – Benefit assessment according to §35a Social Code Book V
Last updated 15.11.2017
Project no.:
A17-40
Commission:
Commission awarded on 15.08.2017 by the Federal Joint Committee (G-BA).
Report type:
Dossier assessment
Status:
Commission completed
Department/Division:
Drug Assessment
Topic:
Cancer
Adult patients with multiple myeloma who have received at least one previous treatment
Monotherapy following progression during pretreatment: added benefit not proven. Combination with bortezomib and dexamethasone: added benefit not proven. With lenalidomide and dexamethasone: added benefit not proven for men, hints of major added benefit for women
After completion of the assessment by IQWiG the Federal Joint Committee (G-BA) conducts a commenting procedure. This may provide supplementary information and as a result lead to a modified benefit assessment. Further information and the decision on the early benefit assessment can be found on the relevant page of the G-BA website.
Federal Joint Committee (G-BA)
2018-02-15 A G-BA decision was published.